Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there. Did your doctor somehow miss the recovery protocol that Pedro Bach-y-Rita used to recover fully back in 1958 with only a partial brain?

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Wednesday, November 18, 2026

Intensive versus standard statin therapy in acute ischemic stroke: a comparative study on the risk of pneumonia and multidrug-resistant bacterial infections

 Still don't have an immediate statin protocol therapy for better recovery? Why hasn't everyone here been fired yet?

Your competent? doctor immediately prescribed statins post stroke based on earlier research, right? NO? And still hasn't been fired yet?

1. Statins.

tested in rats from 2003

http://Statins induce angiogenesis, neurogenesis, and synaptogenesis after stroke Statins induce angiogenesis, neurogenesis, and synaptogenesis after stroke  

Simvastatin Attenuates Stroke-induced Splenic Atrophy and Lung Susceptibility to Spontaneous Bacterial Infection in Mice

Or,

Simvastatin attenuates axonal injury after experimental traumatic brain injury and promotes neurite outgrowth of primary cortical neurons 

October 2012

tested in humans, March 2011

http://www.medwirenews.com/39/91658/Stroke/Acute_statin_therapy_improves_survival_after_ischemic_stroke.html

And now lost even to the Wayback Machine

So, I think this below is the actual research.

Association Between Acute Statin Therapy, Survival, and Improved Functional Outcome After Ischemic Stroke April 2011 

The latest here: 

Intensive versus standard statin therapy in acute ischemic stroke: a comparative study on the risk of pneumonia and multidrug-resistant bacterial infections


  • 1. Department of Neurology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China

  • 2. Department of Clinical Laboratory, Wenzhou Hospital of Integrated Traditional Chinese and Western Medicine, Wenzhou, Zhejiang, China

Abstract

Background: 


The use of intensive statin therapy in acute ischemic stroke (AIS) is common; however, its association with post-stroke pneumonia (PSP) remains uncertain. This study aimed to determine whether intensive-dose atorvastatin (≥40 mg/d) increases the risk, severity, or incidence of multidrug-resistant (MDR) bacterial infections in PSP compared to standard-dose therapy (20 mg/d).


Methods: 


We retrospectively analyzed 4,843 AIS patients admitted to the First Affiliated Hospital of Wenzhou Medical University between January 2020 and January 2022. After applying inclusion and exclusion criteria, 3,199 patients were included. Propensity score matching (PSM) was used to balance baseline characteristics between the intensive and standard atorvastatin groups. The incidence of PSP, pneumonia severity (evaluated by CURB-65 scores), and MDR bacterial infection rates were compared. Multivariate logistic regression was applied to identify independent risk factors for PSP.


Results: 


After PSM, no significant difference was observed in PSP incidence between the intensive and standard atorvastatin groups (8.8% vs. 8.3%, p = 0.691). Multivariate regression confirmed that intensive treatment was not associated with increased PSP risk, either before (OR = 1.074, 95% CI: 0.756–1.525) or after matching (OR = 1.002, 95% CI: 0.672–1.492). Among the 173 PSP patients, there were no significant differences in the proportion of severe pneumonia (21.4% vs. 20.2%, p = 0.863) or MDR bacterial infection incidence (9.5% vs. 10.1%, p = 0.897) between the two groups.


Conclusion: 


High-intensity atorvastatin therapy during the acute phase of ischemic stroke did not increase the risk or severity of pneumonia, nor did it elevate MDR bacterial infections. These findings suggest that intensive atorvastatin therapy is not associated with an increased risk of PSP and offer insights for optimizing clinical treatment strategies.

No comments:

Post a Comment